Skip to main content
Erschienen in: Tumor Biology 4/2012

01.08.2012 | Research Article

Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells

verfasst von: Paloma Silva de Souza, Flavia da Cunha Vasconcelos, Luis Felipe R. Silva, Raquel Ciuvalschi Maia

Erschienen in: Tumor Biology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Multidrug resistance (MDR) is considered a multifactorial phenotype which prevents a successful clinical cancer treatment. This phenomenon is mainly associated with mechanisms that include drug extrusion by P-glycoprotein (Pgp) overexpression and resistance to apoptosis derived by members of the inhibitor of apoptosis proteins (IAPs), such as XIAP. Studies have proposed the use of compounds that are able to inhibit or modulate Pgp function, with no changes in the physiological expression of this protein. Based on that, the present study aimed to evaluate the reversal of MDR phenotype through modulation of Pgp efflux pump activity in leukemia multidrug-resistant cells, using a low dose of cyclosporine A (CsA). We showed that modulation of Pgp activity by using CsA did not induce cytotoxic effects in leukemia cells, independently of Pgp expression. However, during the modulation condition, we could observe that vincristine-induced apoptosis was significant in resistant cells, which was also coupled with decreasing expression of the inhibitor of apoptosis protein XIAP. In summary, our data suggest that CsA is able to reversing MDR phenotype in vitro, inducing sensibility in multidrug-resistant cells with no alterations in Pgp expression. These findings contribute to our knowledge for the circumvention of MDR in cancer cells and could be helpful for new treatment approaches.
Literatur
1.
Zurück zum Zitat Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156–66.PubMed Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156–66.PubMed
2.
Zurück zum Zitat Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25:423––429.PubMed Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25:423––429.PubMed
3.
Zurück zum Zitat Szakacs G, Chen GK, Gottesman MM. The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance. Cancer Biol Ther. 2004;3:382–4.PubMed Szakacs G, Chen GK, Gottesman MM. The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance. Cancer Biol Ther. 2004;3:382–4.PubMed
4.
Zurück zum Zitat Yeh JJ, Hsu NY, Hsu WH, et al. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung. 2005;183:177–83.PubMed Yeh JJ, Hsu NY, Hsu WH, et al. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung. 2005;183:177–83.PubMed
5.
Zurück zum Zitat Kourti M, Vavatsi N, Gombakis N, et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol. 2007;86:166–73.PubMed Kourti M, Vavatsi N, Gombakis N, et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol. 2007;86:166–73.PubMed
6.
Zurück zum Zitat Vander Borght S, Komuta M, Libbrecht L, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008;28:1370–80.PubMed Vander Borght S, Komuta M, Libbrecht L, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008;28:1370–80.PubMed
7.
Zurück zum Zitat Carter A, Dann EJ, Katz T, et al. Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1. Br J Haematol. 2001;114:581–90.PubMed Carter A, Dann EJ, Katz T, et al. Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1. Br J Haematol. 2001;114:581–90.PubMed
8.
Zurück zum Zitat Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003;22:7262–4.PubMed Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003;22:7262–4.PubMed
9.
Zurück zum Zitat Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–27.PubMed Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–27.PubMed
10.
Zurück zum Zitat Vasconcelos FC, Silva KL, Souza PS, et al. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom. 2011;80:158–66.PubMed Vasconcelos FC, Silva KL, Souza PS, et al. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom. 2011;80:158–66.PubMed
11.
Zurück zum Zitat Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008;83:258–64.PubMed Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008;83:258–64.PubMed
12.
Zurück zum Zitat Baran Y, Ural A, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology. 2007;12:497–503.PubMed Baran Y, Ural A, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology. 2007;12:497–503.PubMed
13.
Zurück zum Zitat Krepela E, Dankova P, Moravcikova E, et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol. 2009;35:1449–62.PubMed Krepela E, Dankova P, Moravcikova E, et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol. 2009;35:1449–62.PubMed
14.
Zurück zum Zitat Notarbartolo M, Cervello M, Poma P, et al. Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep. 2004;11:133–6.PubMed Notarbartolo M, Cervello M, Poma P, et al. Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep. 2004;11:133–6.PubMed
15.
Zurück zum Zitat Notarbartolo M, Cervello M, Dusonchet L, et al. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett. 2002;180:91–101.PubMed Notarbartolo M, Cervello M, Dusonchet L, et al. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett. 2002;180:91–101.PubMed
16.
Zurück zum Zitat Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol. 2006;81:824–31.PubMed Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol. 2006;81:824–31.PubMed
17.
Zurück zum Zitat Reis FR, Vasconcelos FC, Pereira DL, et al. Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep. 2011;26:471–8.PubMed Reis FR, Vasconcelos FC, Pereira DL, et al. Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep. 2011;26:471–8.PubMed
18.
Zurück zum Zitat Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105:2916–23.PubMed Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105:2916–23.PubMed
19.
Zurück zum Zitat Schimmer AD, Dalili S, Ried SJ. Targeting XIAP for the treatment of malignancy. Cell Death and Differ. 2006;13:179–88. Schimmer AD, Dalili S, Ried SJ. Targeting XIAP for the treatment of malignancy. Cell Death and Differ. 2006;13:179–88.
20.
Zurück zum Zitat Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709–14.PubMed Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709–14.PubMed
21.
Zurück zum Zitat Fukuda S, Pelus LM. Survivin a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087–98.PubMed Fukuda S, Pelus LM. Survivin a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087–98.PubMed
22.
Zurück zum Zitat Nestal de Moraes G, Silva KL, Vasconcelos FC, et al. Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells. Oncol Rep. 2011;25:1613–9.PubMed Nestal de Moraes G, Silva KL, Vasconcelos FC, et al. Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells. Oncol Rep. 2011;25:1613–9.PubMed
23.
Zurück zum Zitat Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12:835–42.PubMed Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12:835–42.PubMed
24.
Zurück zum Zitat Garrigues A, Nugier J, Orlowski S, et al. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem. 2002;305:106–14.PubMed Garrigues A, Nugier J, Orlowski S, et al. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem. 2002;305:106–14.PubMed
25.
Zurück zum Zitat Qadir M, O’Loughlin KL, Fricke SM, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res. 2005;11:2320–6.PubMed Qadir M, O’Loughlin KL, Fricke SM, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res. 2005;11:2320–6.PubMed
26.
Zurück zum Zitat Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006;106:830–8.PubMed Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006;106:830–8.PubMed
27.
Zurück zum Zitat List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–20.PubMed List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–20.PubMed
28.
Zurück zum Zitat Frydrych I, Mlejnek P, Dolezel P. Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression. Toxicol In Vitro. 2009;23:1482–90.PubMed Frydrych I, Mlejnek P, Dolezel P. Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression. Toxicol In Vitro. 2009;23:1482–90.PubMed
29.
Zurück zum Zitat Rumjanek VM, Trindade GS, Wagner-Souza K, et al. Multidrug resistance in tumor cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc. 2001;73:57–69.PubMed Rumjanek VM, Trindade GS, Wagner-Souza K, et al. Multidrug resistance in tumor cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc. 2001;73:57–69.PubMed
30.
Zurück zum Zitat Robey RW, Steadman K, Polgar O, et al. Pheophorbide A is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004;64:1242–6.PubMed Robey RW, Steadman K, Polgar O, et al. Pheophorbide A is a specific probe for ABCG2 function and inhibition. Cancer Res. 2004;64:1242–6.PubMed
31.
Zurück zum Zitat Vasconcelos FC, Cavalcanti Jr GB, Silva KL, et al. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res. 2007;31:445–54.PubMed Vasconcelos FC, Cavalcanti Jr GB, Silva KL, et al. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res. 2007;31:445–54.PubMed
32.
Zurück zum Zitat Beck WT. Modulators of P-glycoprotein-associated multidrug resistance. Cancer Treat Res. 1991;57:151–70.PubMed Beck WT. Modulators of P-glycoprotein-associated multidrug resistance. Cancer Treat Res. 1991;57:151–70.PubMed
33.
Zurück zum Zitat Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1:93–105.PubMedPubMedCentral Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1:93–105.PubMedPubMedCentral
34.
Zurück zum Zitat McGrogan BT, Gilmartin B, Carney DN, et al. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132.PubMed McGrogan BT, Gilmartin B, Carney DN, et al. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132.PubMed
35.
Zurück zum Zitat Roy MK, Takenaka M, Kobori M, et al. Apoptosis, necrosis and cell proliferation-inhibition by cyclosporine A in U937 (a human monocytic cell line). Pharmacol Res. 2006;53:293–302.PubMed Roy MK, Takenaka M, Kobori M, et al. Apoptosis, necrosis and cell proliferation-inhibition by cyclosporine A in U937 (a human monocytic cell line). Pharmacol Res. 2006;53:293–302.PubMed
36.
Zurück zum Zitat Liu F, Xie ZH, Cai GP, et al. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull. 2007;30:2279–83.PubMed Liu F, Xie ZH, Cai GP, et al. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull. 2007;30:2279–83.PubMed
37.
Zurück zum Zitat Souza PS, Vasconcelos FC, De Souza Reis FR, et al. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol. 2011;39:925–33.PubMed Souza PS, Vasconcelos FC, De Souza Reis FR, et al. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol. 2011;39:925–33.PubMed
38.
Zurück zum Zitat Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5.PubMed Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5.PubMed
39.
Zurück zum Zitat Gibalová L, Sedlák J, Labudová M, et al. Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity. Gen Physiol Biophys. 2009;28:391–403.PubMed Gibalová L, Sedlák J, Labudová M, et al. Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity. Gen Physiol Biophys. 2009;28:391–403.PubMed
40.
Zurück zum Zitat Hu XF, Slater A, Rischin D, et al. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukemia cell line. Br J Cancer. 1999;79:831–7.PubMedPubMedCentral Hu XF, Slater A, Rischin D, et al. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukemia cell line. Br J Cancer. 1999;79:831–7.PubMedPubMedCentral
41.
Zurück zum Zitat Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in pediatric acute lymphoblastic leukemia: implications for mechanisms of therapy failure. Br J Haematol. 2005;131:447–56.PubMed Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in pediatric acute lymphoblastic leukemia: implications for mechanisms of therapy failure. Br J Haematol. 2005;131:447–56.PubMed
42.
Zurück zum Zitat Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia. 2007;21:1172–6.PubMed Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia. 2007;21:1172–6.PubMed
43.
Zurück zum Zitat Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–80.PubMed Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–80.PubMed
44.
Zurück zum Zitat Spoelstra EC, Westerhoff HV, Pinedo HM, et al. The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem. 1994;221:363–73.PubMed Spoelstra EC, Westerhoff HV, Pinedo HM, et al. The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem. 1994;221:363–73.PubMed
45.
Zurück zum Zitat Nagy H, Goda K, Fenyvesi F, et al. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004;315:942–9.PubMed Nagy H, Goda K, Fenyvesi F, et al. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004;315:942–9.PubMed
46.
Zurück zum Zitat Healy E, Dempsey M, Lally C, et al. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int. 1998;54:1955–66.PubMed Healy E, Dempsey M, Lally C, et al. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int. 1998;54:1955–66.PubMed
47.
Zurück zum Zitat List AF, Kopecky KJ, Willman CL. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–20.PubMed List AF, Kopecky KJ, Willman CL. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98:3212–20.PubMed
48.
Zurück zum Zitat Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401–8.PubMed Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401–8.PubMed
49.
Zurück zum Zitat Kim DW, Kim KO, Shin MJ, et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer. 2009;8:1–10. Kim DW, Kim KO, Shin MJ, et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer. 2009;8:1–10.
50.
Zurück zum Zitat Seca H, Lima RT, Guimarães JE, et al. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib. Hematology. 2011;16:100–8.PubMed Seca H, Lima RT, Guimarães JE, et al. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib. Hematology. 2011;16:100–8.PubMed
Metadaten
Titel
Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells
verfasst von
Paloma Silva de Souza
Flavia da Cunha Vasconcelos
Luis Felipe R. Silva
Raquel Ciuvalschi Maia
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0323-5

Weitere Artikel der Ausgabe 4/2012

Tumor Biology 4/2012 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.